Live
FierceBiotechAustralia’s Kazia pays research institute $1.4M for epigenetic platform, preclinical drugFierceBiotechNovo taps OpenAI to deploy AI across R&D, manufacturing and corporate functionsFierceBiotechClick Therapeutics cuts staff after commercial deal restructuringFierceBiotechAstellas to close stem cell unit’s Seattle site, with layoffs incomingFierceBiotechCell therapy biotech Obsidian leverages Galera reverse merger to go publicBioPharma DiveJ&J leans on Tremfya, cancer drugs to overcome Stelara losses10x Genomics BlogWhy 10x Genomics Stock Is Climbing Again - TipRanksEndpoints NewsRevolution Medicines leads latest wave of stock offerings, totaling $1.5BEndpoints NewsEndpoints biopharma sentiment survey for Q2 2026Endpoints NewsHarbinger raises $100M; Astellas to close Seattle siteEndpoints NewsJ&J increasingly confident it can manage Stelara cliff, but work remainsBioPharma DiveLilly boosts ADC portfolio with CrossBridge Bio deal
Endpoints News Apr 14, 2026

FDA approves Travere's Filspari as first drug for the kidney disease FSGS

FDA approves Travere's Filspari as first drug for the kidney disease FSGS

Original
Body unavailable. Use the original source.

Directory

59 All